Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor sitagliptin compared with alpha‐glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin‐1): A multicenter, randomized, open‐label, non‐inferiority trial

Hidetaka Yokoh; Kazuki Kobayashi; Yasunori Sato; Minoru Takemoto; Daigaku Uchida; Azuma Kanatsuka; Nobuichi Kuribayashi; Takashi Terano; Naotake Hashimoto; Kenichi Sakurai; Hideki Hanaoka; Ko Ishikawa; Shunichiro Onishi; Koutaro Yokote;

doi:10.1111/jdi.12282

Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor sitagliptin compared with alpha‐glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin‐1): A multicenter, randomized, open‐label, non‐inferiority trial

Journal of Diabetes Investigation ◽

10.1111/jdi.12282 ◽

2014 ◽

Vol 6 (2) ◽

pp. 182-191 ◽

Cited By ~ 12

Author(s):

Hidetaka Yokoh ◽

Kazuki Kobayashi ◽

Yasunori Sato ◽

Minoru Takemoto ◽

Daigaku Uchida ◽

...

Keyword(s):

Type 2 Diabetes ◽

Japanese Patients ◽

Efficacy And Safety ◽

Open Label ◽

Dipeptidyl Peptidase 4 ◽

Glucosidase Inhibitor ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Alpha Glucosidase ◽

Control Diabetes

Download Full-text

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-i

Diabetes Obesity and Metabolism ◽

10.1111/dom.12264 ◽

2014 ◽

Vol 16 (8) ◽

pp. 761-765 ◽

Cited By ~ 12

Author(s):

K. Kobayashi ◽

H. Yokoh ◽

Y. Sato ◽

M. Takemoto ◽

D. Uchida ◽

...

Keyword(s):

Type 2 Diabetes ◽

Japanese Patients ◽

Dipeptidyl Peptidase ◽

Efficacy And Safety ◽

Open Label ◽

Dipeptidyl Peptidase 4 ◽

Glucosidase Inhibitor ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase‐4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24‐week, open‐label, controlled trial ( STOP‐OB )

Diabetes Obesity and Metabolism ◽

10.1111/dom.14059 ◽

2020 ◽

Vol 22 (9) ◽

pp. 1659-1663 ◽

Cited By ~ 1

Author(s):

Toru Kitazawa ◽

Hiroaki Seino ◽

Hiroshi Ohashi ◽

Takeshi Inazawa ◽

Masahiro Inoue ◽

...

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Dipeptidyl Peptidase ◽

Oral Agent ◽

Open Label ◽

Dipeptidyl Peptidase 4 ◽

The Third ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F)

Diabetology International ◽

10.1007/s13340-020-00426-w ◽

2020 ◽

Vol 11 (3) ◽

pp. 274-282

Author(s):

Yuichi Terawaki ◽

◽

Chikayo Iwaya ◽

Takashi Nomiyama ◽

Dai Shimono ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Japanese Patients ◽

Dipeptidyl Peptidase ◽

Efficacy And Safety ◽

Dipeptidyl Peptidase 4 ◽

Insulin Secretagogue ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Efficacy and safety of combination therapy with an α-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta-analysis

Journal of Diabetes Investigation ◽

10.1111/jdi.12754 ◽

2017 ◽

Vol 9 (4) ◽

pp. 893-902 ◽

Cited By ~ 6

Author(s):

Se Hee Min ◽

Jeong-Hwa Yoon ◽

Seokyung Hahn ◽

Young Min Cho

Keyword(s):

Diabetes Mellitus ◽

Systematic Review ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Meta Analysis ◽

Efficacy And Safety ◽

Dipeptidyl Peptidase 4 ◽

Glucosidase Inhibitor ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination

Expert Opinion on Pharmacotherapy ◽

10.1517/14656566.2014.939070 ◽

2014 ◽

Vol 15 (13) ◽

pp. 1785-1795 ◽

Cited By ~ 2

Author(s):

Yuri Ono ◽

Hikaru Kamoshima ◽

Akinobu Nakamura ◽

Hiroshi Nomoto

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Japanese Patients ◽

Metabolic Responses ◽

Fixed Dose ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Dose Combination

Download Full-text

Decision letter for "Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicenter study: The L"

10.1111/dom.14036/v3/decision1 ◽

2020 ◽

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Fixed Ratio ◽

Japanese Patients ◽

Efficacy And Safety ◽

Oral Antidiabetic Drugs ◽

Open Label ◽

Oral Antidiabetic

Download Full-text

Decision letter for "Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicenter study: The L"

10.1111/dom.14036/v2/decision1 ◽

2020 ◽

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Fixed Ratio ◽

Japanese Patients ◽

Efficacy And Safety ◽

Oral Antidiabetic Drugs ◽

Open Label ◽

Oral Antidiabetic

Download Full-text

Review for "Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicenter study: The L"

10.1111/dom.14036/v1/review1 ◽

2019 ◽

Author(s):

Graydon Meneilly

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Fixed Ratio ◽

Japanese Patients ◽

Efficacy And Safety ◽

Oral Antidiabetic Drugs ◽

Open Label ◽

Oral Antidiabetic

Download Full-text

Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12631 ◽

2016 ◽

Vol 18 (5) ◽

pp. 528-532 ◽

Cited By ~ 12

Author(s):

S. Hong ◽

C.-Y. Park ◽

K. A. Han ◽

C. H. Chung ◽

B. J. Ku ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

Diabetes Obesity and Metabolism ◽

10.1111/j.1463-1326.2008.01016.x ◽

2009 ◽

Vol 11 (2) ◽

pp. 167-176 ◽

Cited By ~ 114

Author(s):

R. E. Pratley ◽

M. S. Kipnes ◽

P. R. Fleck ◽

C. Wilson ◽

Q. Mekki ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Efficacy And Safety ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text